Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company offers generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparat… Read more
Antibiotice Ia (ATB) - Net Assets
Latest net assets as of September 2025: RON922.94 Million RON
Based on the latest financial reports, Antibiotice Ia (ATB) has net assets worth RON922.94 Million RON as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RON1.40 Billion) and total liabilities (RON477.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RON922.94 Million |
| % of Total Assets | 65.91% |
| Annual Growth Rate | 11.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 11.51 |
Antibiotice Ia - Net Assets Trend (2020–2024)
This chart illustrates how Antibiotice Ia's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Antibiotice Ia (2020–2024)
The table below shows the annual net assets of Antibiotice Ia from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | RON894.31 Million | +5.59% |
| 2023-09-30 | RON846.96 Million | +32.04% |
| 2022-09-30 | RON641.43 Million | +6.02% |
| 2021-09-30 | RON604.99 Million | +4.80% |
| 2020-09-30 | RON577.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Antibiotice Ia's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 24983354100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RON201.07 Million | 22.48% |
| Other Components | RON693.24 Million | 77.52% |
| Total Equity | RON894.31 Million | 100.00% |
Antibiotice Ia Competitors by Market Cap
The table below lists competitors of Antibiotice Ia ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DIO Corporation
KQ:039840
|
$94.83 Million |
|
Tuan Sing Holdings Limited
STU:TUS
|
$94.85 Million |
|
Power Engineering Consulting JSC 2
VN:TV2
|
$94.87 Million |
|
CROSSJECT SA EO -10
F:74C
|
$94.89 Million |
|
Elentec Co. Ltd
KQ:054210
|
$94.81 Million |
|
Highlight Tech
TWO:6208
|
$94.80 Million |
|
Indonesian Paradise Property
JK:INPP
|
$94.75 Million |
|
Plby Group Inc
NASDAQ:PLBY
|
$94.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Antibiotice Ia's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 846,964,120 to 894,308,823, a change of 47,344,703 (5.6%).
- Net income of 102,202,828 contributed positively to equity growth.
- Dividend payments of 48,168,486 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RON102.20 Million | +11.43% |
| Dividends Paid | RON48.17 Million | -5.39% |
| Other Changes | RON-6.69 Million | -0.75% |
| Total Change | RON- | 5.59% |
Book Value vs Market Value Analysis
This analysis compares Antibiotice Ia's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.34x to 1.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-09-30 | RON0.86 | RON2.02 | x |
| 2021-09-30 | RON0.90 | RON2.02 | x |
| 2022-09-30 | RON0.96 | RON2.02 | x |
| 2023-09-30 | RON1.26 | RON2.02 | x |
| 2024-09-30 | RON1.33 | RON2.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Antibiotice Ia utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.43%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.14%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.43x
- Recent ROE (11.43%) is above the historical average (7.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 4.57% | 7.75% | 0.39x | 1.49x | RON-31.34 Million |
| 2021 | 4.95% | 8.18% | 0.41x | 1.48x | RON-30.56 Million |
| 2022 | 8.02% | 10.64% | 0.56x | 1.34x | RON-12.67 Million |
| 2023 | 9.57% | 13.50% | 0.53x | 1.35x | RON-3.61 Million |
| 2024 | 11.43% | 15.14% | 0.53x | 1.43x | RON12.77 Million |
Industry Comparison
This section compares Antibiotice Ia's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $724,246,398
- Average return on equity (ROE) among peers: 17.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Antibiotice Ia (ATB) | RON922.94 Million | 4.57% | 0.52x | $94.81 Million |
| Biofarm Bucure (BIO) | $257.23 Million | 19.78% | 0.35x | $128.28 Million |
| ZENTIVA S.A. (SCD) | $1.19 Billion | 16.17% | 0.26x | $26.35 Million |